Clinical Trial Update: Phase III Study of 5LGr to Treat Tic Disorder [Phase 3]

View source ↗

Summary

Phase III trial of 5LGr for tic disorders has completed, including Tourette syndrome and chronic tic disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tic Disorder
• Tourette Syndrome

Drugs mentioned

• 5LGr

Snippet

Sponsor: Tasly Pharmaceuticals, Inc. | Conditions: Tic Disorder, Tourette Syndrome | Phase 3 | Status: COMPLETED